1028486-06-7

Upstream product

• 869365-89-9 (2-amino-5-chlorophenyl)(2-fluoro-6-methoxyphenyl)methanone 
• 869367-33-9 8-chloro-4-[(dimethylamino)methylene]-1-(2-fluoro-6-methoxyphenyl)-3,4-dihydro-5H-2-benzazepin-5-one 
• 869367-01-1 8-chloro-1-(2-fluoro-6-methoxyphenyl)-3,4-dihydrobenzo[c]azepin-5-one 
• 1332307-86-4 methyl 4-{[ammo(imino)methyl]amino}-2-methoxybenzoate nitrate 
• 1233025-91-6 (5-chloro-2-iodophenyl)(2-fluoro-6-methoxyphenyl)methanone 
• 1028486-01-2 alisertib 
• 869366-70-1 tert-butyl {3-[4-chloro-2-(2-fluoro-6-methoxybenzoyl)phenyl]prop-2-yn-1-yl}carbamate 
• 28910-83-0 (2-amino-5-chlorophenyl)-(2,6-difluorophenyl)methanone 
• 869365-97-9 (5-chloro-2-iodophenyl)(2,6-difluorophenyl)methanone 
• 27492-84-8 Methyl 4-amino-2-methoxybenzoate 
• 1310-73-2 sodium hydroxide 

Relevant academic research and scientific papers

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

The Aurora kinases are essential for cell mitosis, and the dysregulation of Aurora A and B have been linked to the etiology of human cancers. Investigational agents MLN8054 (8) and alisertib (MLN8237, 10) have been identified as high affinity, selective,

CRYSTALLINE FORMS OF SODIUM 4-{[9-CHLORO-7-(2-FLUORO-6--METHOXYPHENYL)-5H -PYRIMIDO[5,4-D][2]BENZAZEPIN-2YL]AMINO}-2-METHOXYBENZOATE

The present invention is directed to a compound of formula (Z): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form

COMPOUNDS FOR INHIBITING MITOTIC PROGRESSION

The present invention relates to compounds of formula (I) : and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.